12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Faldaprevir: Additional Phase IIa data

Data from 13 evaluable treatment-naïve patients with HCV genotype 1a infection in a double-blind, U.S. Phase IIa trial showed that an all-oral regimen of deleobuvir and faldaprevir from Boehringer and PPI-668 from Presidio Pharmaceuticals Inc. (San Francisco, Calif.) with ribavirin for 12 weeks led to an SVR 4 weeks after end of treatment in 100% of patients....

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >